1. BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives
   Eleonora Molinaro et al, 2020, Cancers CrossRef
2. Hepatocarcinoma Angiogenesis and DNA Damage Repair Response: An Update
   Xi-Dai Long et al, 2019, DNA Repair- An Update CrossRef
3. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update
   Priyancy G. Jain et al, 2019, European Journal of Medicinal Chemistry CrossRef
4. Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
   Abdullah Alhusaini et al, 2021, Biomedicines CrossRef
5. Inhibition of poly (ADP-ribose) Polymerase-1 (PARP-1) improves endothelial function in pulmonary hypertension
   Mohammad Shafiq et al, 2023, Pulmonary Pharmacology & Therapeutics CrossRef
6. PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine
   Francisco Quiñonero et al, 2022, Biomedicine & Pharmacotherapy CrossRef
7. Poly(ADP-Ribose) Polymerase Inhibition as a Promising Approach for Hepatocellular Carcinoma Therapy
   Alexia Paturel et al, 2022, Cancers CrossRef
8. Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer
   Francisco Quiñonero et al, 2023, International Journal of Nanomedicine CrossRef
9. Tissue Inhibitor of Metalloproteinase 3: Unravelling Its Biological Function and Significance in Oncology
   Wei-Ting Lee et al, 2024, International Journal of Molecular Sciences CrossRef
10. Targeting BRCA‐mutant biliary tract cancer: Current evidence and future perspectives
    Xin Yu Li et al, 2023, Journal of Digestive Diseases CrossRef
11. Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysis
    Xinyi Lei et al, 2021, Human Genomics CrossRef